













	Berry	 and	 colleagues	 report	 that	 presynaptic	 striatal	 dopamine	 synthesis	capacity	(measured	with	[18F]FMT	PET)	is	not	associated	with	methylphenidate-induced	 striatal	 dopamine	 release	 (indexed	 as	 a	 reduction	 in	 [11C]raclopride	non-displaceable	 binding-potential)	 in	 healthy	 participants	 (Berry	 et	 al,	 2017).	The	 authors	 should	 be	 commended	 for	 the	 quality	 of	 this	 study,	 in	 which	 40	subjects	each	received	three	PET	scans	within	a	short	time	window.	The	results	are	 pertinent	 to	 the	 interpretation	 of	 neuroimaging	 studies	 investigating	 the	dopamine	hypothesis	of	schizophrenia.		Multiple	 lines	 of	 evidence	 indicate	 that	 presynaptic	 striatal	 dopamine	dysfunction	 is	 central	 to	 the	 pathoetiology	 of	 schizophrenia.	 Striatal	 dopamine	synthesis	 capacity	 (also	 interpreted	 as	 dopamine	 turnover)	 is	 elevated	 in	patients	 compared	 with	 healthy	 participants	 (Howes	 et	 al,	 2012).	 Moreover,	patients	 show	 exaggerated	 striatal	 dopamine	 release	 in	 response	 to	 0.3mg/kg	intravenous	 amphetamine	 (measured	with	 [123I]IBZM]-SPECT)(Abi-Dargham	 et	al,	1998).	A	parsimonious	hypothesis	is	that	these	findings	represent	two	facets	of	 the	 same	 underlying	 presynaptic	 dopamine	 dysfunction	 in	 schizophrenia.	Thus,	 the	 lack	 of	 a	 relationship	 between	 dopamine	 synthesis	 capacity	 and	methylphenidate-induced	 dopamine	 release	 in	 healthy	 participants	 warrants	further	consideration.			In	 contrast	 to	 the	 study	 of	 Berry	 and	 colleagues,	 the	 majority	 of	 PET/SPECT	studies	 investigating	dopamine	synthesis	capacity	and	release	 in	schizophrenia	used	[18F]DOPA	or	 [11C]DOPA,	 and	amphetamine	challenge	 (Abi-Dargham	et	 al,	1998;	Howes	et	 al,	 2012).	As	 the	authors	note,	FMT	and	DOPA	are	 sensitive	 to	different	aspects	of	presynaptic	dopamine	function.	Moreover,	amphetamine	and	methylphenidate	promote	dopamine	efflux	via	divergent	mechanisms.	Whereas	both	 stimulants	 block	 the	 presynaptic	 dopamine	 transporter	 (DAT),	 recent	studies	 using	 fast-scan	 cyclic	 voltammetry	 in	 freely	 moving	 rats	 suggest	 that	amphetamine	(1mg/kg)	causes	dopamine	release	via	action	potential-dependent	mechanisms.	 These	 include	 increased	 frequency,	 amplitude	 and	 duration	 of	spontaneous	 dopamine	 transients,	 which	 ride	 on-top	 of	 a	 more	 sustained	dopamine	accumulation	(Covey	et	al,	2016;	Daberkow	et	al,	2013).	At	this	dose	amphetamine	 also	 augments	 phasic	 dopamine	 responses	 to	 reward-predicting	cues,	whilst	 at	higher	doses	 (5mg/kg)	 it	decouples	dopamine	burst	 firing	 from	behaviorally-relevant	 cues,	 with	 a	 corresponding	 breakdown	 in	 goal-directed	behavior	(Daberkow	et	al,	2013).	At	high	cytoplasmic	concentrations,	as	can	be	achieved	in	brain-slice	preparations,	amphetamine	also	causes	redistribution	of	vesicular	dopamine	and	reversal	of	DAT.			Amphetamine-induced	dopamine	release	in	vivo	therefore	reflects	the	sensitivity	and	 capacity	 of	 presynaptic	 dopamine	 neurons	 to	 increase	 spontaneous	transients	 under	 task-neutral	 conditions	 (Covey	 et	 al,	 2016;	 Daberkow	 et	 al,	2013),	 in	 a	 way	 that	 methylphenidate-induced	 release	 does	 not.	 It	 has	 been	proposed	 that	 this	 sensitivity	 under	 amphetamine	 may	 correlate	 with	 a	 more	general	 tendency	 towards	 spontaneous	 dopamine	 transients	 in	 the	 drug-free	state	(Maia	&	Frank,	2017).	This	would	result	in	increased	presynaptic	dopamine	
turnover,	 and	 manifest	 as	 a	 positive	 relationship	 between	 PET	 measures	 of	dopamine	 synthesis	 capacity	 and	 amphetamine-induced	 dopamine	 release,	 but	not	 methylphenidate-induced	 release,	 which	may	 be	 more	 dependent	 on	 DAT	function.	 Interestingly,	 one	 study	 in	 advanced	 Parkinson’s	 Disease	 patients	reported	 a	 positive	 correlation	 between	 putamen	 [18F]DOPA	 uptake	 and	methamphetamine-induced	dopamine	release	(R2=0.69-0.74)(Piccini	et	al,	2003).			Under	 this	 hypothesis,	 the	 findings	 of	 increased	 dopamine	 synthesis	 and	amphetamine-induced	 release	 capacity	 in	 schizophrenia	 may	 indeed	 reflect	 a	single	underlying	abnormality,	namely	increased	phasic	dopaminergic	responses	to	behaviorally-irrelevant	cues,	as	proposed	by	the	aberrant	salience	hypothesis	(Howes	&	Nour,	2016;	Kapur,	2003).	Future	PET	studies	that	measure	dopamine	synthesis	 and	 amphetamine-induced	 release	 capacity	 in	 patients	 and	 healthy	controls	are	necessary	to	test	this	hypothesis.			
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